Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that is genetically complex. There is evidence supporting a role of myelin oligodendrocyte glycoprotein (MOG) humoral immunity in MS. We aimed to determine the genetic regulation of anti-MOG antibodies and their involvement in disease, by using MOG-induced experimental autoimmune encephalomyelitis (EAE) in rat, an animal model that closely mimics human MS. We show polygenic regulation of anti-MOG antibodies in two backcross populations, including a major genetic determinant for antibody expression on chromosome 4, Amig3. We fine-mapped the region to 539 kilobases (kb) consisting of a complex of seven C-type lectin receptor genes (Dcir4, Dcir3, Dcir2, Dcir1, Dcar1, Mcl and Mincle) that was captured in the APLEC congenic strain. We confirmed that Amig3 regulates anti-MOG antibody levels in MOG-EAE, and further showed that immune reactions during initiation of EAE were skewed toward increased numbers of B cells in the EAE-protected APLEC strain, together with higher anti-MOG IgG1 and lower IgG2b levels. Taken together, our data demonstrated complex regulation of the antibody response during EAE and that skewing the antibody response toward Th2 contributed to protection from EAE.
INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that is a complex disorder triggered in genetically susceptible individuals by environmental factors and stochastic events. The clinical, pathological and immunological phenotypes of MS patients vary, and the heterogeneity extends to both the genetic and the pathogenic mechanisms involved in disease.
The importance of B cells and autoantibodies in the pathogenesis of MS has recently been revisited. The presence of oligoclonal bands in the cerebrospinal fluid (CSF) of MS patients, 1 which is also a part of the diagnostic procedure, implicates a role of B cells in MS. Moreover, B-cell follicle-like aggregates have been reported in the meninges of secondary progressive MS cases. 2 More recently, the efficacy of the treatment with the B-cell depleting monoclonal antibody rituximab in some MS patients 3 provides further evidence for the critical role of B cells in disease pathogenesis. The presence of antibodies against myelin oligodendrocyte glycoprotein (MOG) in lesions of MS patients supports the role of anti-MOG humoral immunity in MS. 4 In addition, the increased levels of antibodies to MOG in the serum and CSF of MS patients relative to controls are suggestive of their involvement in disease pathogenesis. 5, 6 Such antibodies have been shown to bind to MOG in human MS lesions and may be responsible for the disintegration of the myelin sheaths. 4 Nonetheless, the role of MOG as an instrumental antibody target in MS is still debated. 7 The ongoing challenge is to elucidate the molecular mechanisms involved in MS pathogenesis and specifically the causative mechanisms conferred by MS risk genes. Such studies can be facilitated by analyses of complimentary features of disease and their relationship with the clinical outcome. This combinatorial approach has successfully been used to identify MS and experimental autoimmune encephalomyelitis (EAE)-regulating genes. 8, 9 Furthermore, it has been useful in identifying genes and addressing their functions in other diseases such as rheumatoid arthritis 10 and type 1 diabetes. 11 Thus, our aim was to determine how the anti-MOG antibodies are genetically regulated and how their levels correlate with disease, by using MOG-induced EAE, an animal model that closely mimics human MS. MOG has a unique ability to elicit a synergistic encephalitogenic T cell and demyelinating autoantibody response, two key components of MS. Anti-MOG antibodies exacerbate disease severity and initiate demyelination in central nervous system autoimmune diseases in mouse, rat and primate models of EAE. [12] [13] [14] Different inbred rat strains have both variable susceptibility to EAE and different capacity to raise anti-MOG antibodies. [15] [16] [17] For example, the DA rat strain is susceptible upon EAE induction whereas PVG rat strain is EAE resistant. Crossing the strains with varying susceptibility to establish populations where each rat is genetically unique and using the within-cross variability in inherited genotypes and phenotype expression enables the investigation of genetic regulation of the anti-MOG IgG response, including different IgG isotypes, and their contribution to clinical EAE.
We analyzed the anti-MOG IgG response in backcross and intercross populations, and a congenic strain and show polygenic regulation that is isotype and time specific, suggesting substantial complexity in the antibody response. Among the quantitative trait loci (QTLs), we identified a major regulator, Amig3, which was finemapped to a 539-kb region that harbors a gene cluster encoding C-type lectin receptors that determine the anti-MOG IgG response. Understanding how the resulting anti-MOG IgG levels modulate clinical progression can provide insight into the pathological mechanism involving B-cell immunity and antibody production, and how these are controlled by the risk genes that influence EAE.
RESULTS
Anti-MOG IgG levels correlate with disease susceptibility and severity We measured anti-MOG antibodies (for data distribution see Supplementary Figure 1 ) in 421 (DAxPVG)xDA and 471 (DAxPVG)xPVG backcross rats (hereafter referred to as DABC and PVGBC, respectively) at the onset and late phase of EAE to determine how their levels correlate with disease.
To evaluate the contribution of different anti-MOG IgG isotypes to EAE, we compared rats affected by EAE with those who remained healthy. Sick rats displayed higher levels of anti-MOG IgG, IgG1, IgG2b and IgG2c at the onset of disease in both crosses (Figures 1a and b) . During the later phase of EAE, the anti-MOG IgG1 response became higher in healthy rats (Figure 1a ), whereas total IgG and IgG2b levels remained higher in affected rats compared with healthy rats (Figure 1a ). However, in general, the differences in antibody levels between healthy and sick rats were more pronounced at the onset of disease.
To evaluate how anti-MOG IgG isotypes influence EAE severity, we studied correlation of anti-MOG IgG levels with different clinical parameters of EAE at different phases of disease. The antibodies measured during disease onset are largely influenced by initiation of inflammation and their association to subsequent disease, therefore, indicate the effect that the ability to mount a response has on disease progression. The antibody levels measured later after disease onset modulate EAE progression but are also influenced by the inflammatory processes taking place, and must therefore be analyzed in the context of change from early levels. High levels of anti-MOG IgG, and more specifically anti-MOG IgG2b, at the onset of disease correlated with subsequent development of more severe EAE, represented by the cumulative EAE score in both DABC (Figure 2a ) and PVGBC (Figure 2b ) populations. Consistent with this, high anti-MOG IgG2b levels during the late phase of EAE remained correlated with more severe disease in DABC rats (Table 1) , although this correlation was Figure 1 . EAE-affected rats have higher anti-MOG antibody levels than healthy rats. Anti-MOG IgG and IgG isotype arbitrary unit (AU) levels measured by enzyme-linked immunosorbent assay at early (day 12 p.i.) and late (day 35 p.i. in DABC and day 21 p.i. in PVGBC) in (a) 421 DABC rats and (b) 471 PVGBC rats. Anti-MOG antibodies dilution factor: for IgG 1:10 000; for IgG1 1:200 (in DABC) and 1:1000 (in PVGBC); for IgG2b 1:2000 (in DABC) and 1:10 000 (in PVGBC) and for IgG2c 1:200. Differences between sick and healthy rats were tested using nonparametric Mann-Whitney test in GraphPad Prism 5.0. *Po0.05, **Po0.01; ***Po0.001; ****Po0.0001. Error bars represent s.e.m. weaker. High anti-MOG IgG1 levels during the early phase of disease also corresponded with higher cumulative EAE scores in both crosses (Figures 2a and b) . Conversely, high levels of IgG1 during the later time point correlated with lower incidence and shorter duration (Table 1) , which may reflect disease protection in rats that mount a higher IgG1 response. Considering that IgG isotypes often reflect immune reactions of different qualities, we asked whether the ratio between specific isotypes, in addition to the level of each isotype, could be important for disease. Indeed, the ratio of IgG1/IgG2b both at the early and late disease stages was negatively correlated with the cumulative EAE score in DABC ( Figure 2a and Table 1) , showing a protective effect.
Polygenic regulation of anti-MOG antibodies with isotype-specific QTLs The within-cross variability in anti-MOG IgG isotype levels and EAE reflects the difference in genetic constitution between individuals in a population. This genetic variability enables identification of loci that contribute to disease. We next performed genome-wide linkage analyses to investigate the genetic regulation of anti-MOG IgG levels. The polygenic nature of EAE shown in other studies was also found in our study of anti-MOG antibody responses ( Figure 3 and Table 2 ). Several QTLs were identified, and genetic regulation of the anti-MOG antibody response differed between the susceptible and resistant crosses. In addition, the genetic influence over antibody response differed throughout the disease course within each cross and a few QTLs seemed to also to be sex specific.
The genetic regulation of anti-MOG IgG levels was different during disease onset than during the late phase of disease. Two loci, on chromosomes 4 (Amig3) and 9, determine the antibody levels at day 12 post immunization (p.i.) in the DABC (Figure 4a ), which represents the time of EAE onset. IgG levels stratified on genotype at the peak markers show that PVG alleles in both QTLs predisposed for higher anti-MOG IgG levels ( Figure 3b ). Conversely, in both QTLs that regulated the IgG response during chronic disease, at day 35, DA alleles predisposed for higher anti-MOG IgG levels (Figure 4b ). Antibody levels in the late phase of disease were regulated by a locus on chromosome 10 ( Figure 4a ) and Amig1 on chromosome 3, which mapped in 213 DABC female rats but was only suggestive in the whole DABC population.
We next investigated the regulation of anti-MOG IgG isotypes to identify QTLs that influence isotype-specific responses. The IgG1 and IgG2b responses were regulated by unique sets of loci and these differed in early compared with late EAE, suggesting vast complexity in the genetic regulation of the antibody response. In the DABC, the anti-MOG IgG1 isotype-specific response was linked to Amig3 during the disease onset, and higher antibody levels were found in carriers of PVG alleles at the peak marker (Figure 5a ). Amig3 continued to regulate IgG1 antibodies during the late phase of EAE in both DABC (Figure 5b ) and PVGBC ( Table 2 ). In contrast, the anti-MOG IgG2b isotype-specific response during the onset was regulated by a QTL on chromosome 8, with DA alleles driving higher IgG2b expression (Figure 5a ). The IgG2b response during chronic disease was regulated by a locus on chromosome 10, Amig4, also with DA alleles predisposing for higher IgG2b levels ( Figure 5b ).
Amig3 is the major regulator of anti-MOG IgG levels Although the antibody response to MOG is polygenic and complex, Amig3 is the most significant QTL in both crosses and at both time points. Hence, Amig3 is the major regulator of anti-MOG IgG isotype levels ( Table 2 ). To more closely define Table 1 ) and PVG alleles predisposed for higher antibody levels in both phenotypes (Figure 6b ). The refined Amig3 region contains a cluster of antigen-presenting lectin-like receptors, preferentially expressed on neutrophils and antigen-presenting cells such as dendritic cells, macrophages and B cells. 18 APLEC genes confer high anti-MOG IgG1 and low IgG2b, and protect against EAE To further confirm and validate the role of Amig3 in anti-MOG antibody responses and subsequent MOG-EAE, we used a congenic strain, APLEC, in which a 534-kb fragment from the PVG strain was transferred onto the DA-susceptible background. The APLEC fragment contains seven confirmed antigen-presenting lectin-like receptor genes (Dcir4, Dcir3, Dcir2, Dcir1, Dcar1, Mcl and Mincle) and two predicted genes ( Figure 6c ). MOG-EAE was induced in female APLEC and inbred DA rats that were monitored for 40 days for clinical signs of the disease. Serum anti-MOG IgG, IgG1, IgG2b and IgG2c isotype levels were determined by enzyme-linked immunosorbent assay at day 25 and day 40 p.i. As expected, APLEC had an increased IgG1 response and decreased IgG2b response at both time points compared with DA (Figures 7a and b) . The ratio IgG1/IgG2b was also much higher in the congenic rats (Figures 7a and b) . No significant differences were observed in anti-MOG IgG or IgG2c isotype levels between the APLEC and DA strains (data not shown). In addition, anti-MOG antibody levels were measured in CSF at the end of the experiment. The anti-MOG IgG isotype levels in CSF displayed the same differences between APLEC and DA rats as in the serum (data not shown).
The upregulation of IgG1 and downregulation of IgG2b in APLEC rats was associated with protection from EAE ( Figure 8a and Table 3 ). All of the DA rats developed EAE (100%), whereas only 50% of APLEC rats showed any clinical signs of disease (Po0.007). Furthermore, APLEC rats had milder EAE, with a later disease onset (Po0.0002), reduced cumulative and maximum score (Po0.0002 and Po0.001, respectively), and shorter duration of disease (Po0.0002; Figure 8b , Table 3 ). These results show that in addition to regulating anti-MOG IgG levels, Amig3 influence MOG-EAE susceptibility and severity.
APLEC genes control the size and response of the B-cell compartment To assess how the APLEC region influences immune reactions during initiation of EAE, we collected inguinal lymph nodes from DA and APLEC female rats 7 days after MOG immunization. There were differences in cell numbers infiltrating the lymph nodes ( Figure 9 ), with APLEC rats having higher total cell numbers compared with DA rats (Figure 9a) . Furthermore, the proportions of immune cells in the APLEC strain were skewed toward B cells, with increased CD45RA þ B-cell numbers (P ¼ 0.0417) and less There was also a decrease in CD3 þ CD4 þ T-cell numbers and increase in FoxP3 þ regulatory T cells in APLEC rats compared with DA, although these differences did not reach statistical significance ( Figure 9c ). We also observed a significantly lower percentage of tumor necrosis factor (TNF)-producing CD3 þ CD4 þ T cells (P ¼ 0.0423), TNF-producing CD3 þ CD8 þ T cells (P ¼ 0.0065) and TNF-producing CD3 À cells (P ¼ 0.0120) in APLEC compared with DA rats (Figure 9d ).
DISCUSSION
Genome-wide analysis in two large rat backcrosses identified polygenic regulation of anti-MOG IgG levels, their correlation with Allelic effect plots at the peak marker of each QTL for early -Amig3 and chromosome 9, and late -chromosomes 3 and 10, antibody response. Thresholds, indicated by the black (early) and gray (late) lines, for 95% significant linkage are 2.8 and 2.7, respectively. P-values given in the allelic effect plots were calculated using nonparametric Mann-Whitney test in GraphPad Prism 5.0. DA/DA and DA/PVG alleles are indicated with DD and DP, respectively. 
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EAE susceptibility and severity, and established Amig3 on chromosome 4 as the major genetic regulator of anti-MOG IgG levels. Amig3 was fine-mapped in an AIL to a 539-kb region that contains seven functional C-type lectin-like genes. Introgression of the PVG alleles at the APLEC locus on the susceptible DA background resulted in a skewed anti-MOG response and protection from EAE. This shows that polymorphism(s) in APLEC genes regulate both anti-MOG IgG levels and MOG-EAE, and suggests a common pathway. Amig3 overlaps many QTLs for inflammatory phenotypes, including Oia2, Cia13 and Pia7 that have been associated with oil-, type II collagen-and pristane-induced arthritis, respectively.
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Amig3 also overlaps Eae20 that confers protection against MOG-EAE. 22 Furthermore, Amig3 overlaps Iddm14 that regulates glucose levels in type 1 diabetes in rat. 23 This indicates that genetic polymorphisms in this locus may influence immune regulation involved in organ-specific autoimmune diseases in general. Furthermore, previous studies have already identified broad regions overlapping Amig3 as anti-MOG IgG-and IgE-regulating in EAE. 24 In addition, a broad region encompassing Amig3 has been identified to regulate anticollagen antibodies in rats (Ciaa4). 25 However, these regions were too vast to support the identification of candidate genes. Therefore, after our initial analysis in backcross populations, we refined the Amig3 influence using high-resolution mapping in an AIL. 26 In DABC and PVGBC, Amig3 on chromosome 4 appeared to be the most important regulator of anti-MOG IgG isotype levels. In the same crosses, Amig3 regulated EAE susceptibility and severity (Stridh et al., Stockholm, Sweden, unpublished data), which further supports the role of anti-MOG antibodies in the development of EAE. The (DAxPVG) G10 AIL fine-mapped Amig3 into a 539-kb region spanning from 159.4 to 159.9 Mb, on chromosome 4, and showed strong linkage to total anti-MOG IgG levels and IgG1 isotype-specific levels.
We further confirmed and studied the Amig3 region in isolation in the APLEC congenic strain. APLEC rats harbor seven functional genes (Dcir4, Dcir3, Dcir2, Dcir1, Dcar1, Mcl and Mincle) that encode a complex of antigen-presenting lectin-like receptors, preferentially expressed on neutrophils and antigen-presenting cells such as dendritic cells, macrophages and B cells. 18 The C-type lectins are transmembrane proteins with diverse motifs in their intracellular part. Alleles from the resistant PVG strain in APLEC significantly protected rats from EAE. In addition, we observed higher B-cell frequency in the lymph nodes of immunized APLEC rats and lower frequency of CD8-cell and cells producing TNF compared with DA controls. Together, this implies a role of APLEC genes on T-and B-cell interaction. Recently, the impact of APLEC genes on frequency of B cells in the total naive leukocyte population in the peripheral blood has been shown using other inbred rat strains. 27 Taken together, variants in APLEC genes determine the response of T and B cells that can result in skewing the immune response toward the Th2 pathway, reflected in higher anti-MOG IgG1 levels, and thereby protecting from EAE. In contrast, the IgG2b response that is preferentially induced by interferon-g-producing Th1 cells 28 was higher in the DA strain and associated with more severe disease. Rodent Dcir1 and Dcir2 have immunoreceptor tyrosine-based inhibitory motifs, predicting an inhibitory function. 29 It has also been shown that the mouse Dcir1 receptors originally identified as an immunoreceptor tyrosinebased inhibitory motif-bearing immunoreceptor expressed on antigen-presenting cells, actually acts as an immunoreceptor tyrosine-based inhibitory motif-dependent inhibitory receptor for B cells. 30 Furthermore, Dcir-deficient mice exhibited higher anticollagen II IgG1 isotype levels compared with the wild-type mice, in collagen-induced arthritis. 31 On the other hand, Dcar1 is closely related to Dcir but it introduces activating signals through its functional association with the immunoreceptor tyrosine-based activating motif-bearing Fc receptor-g chain. 29 In the DA strain, Figure 8 . APLEC congenic rats are protected from EAE compared with the DA rats. DA and APLEC female rats were immunized with MOG in incomplete Freund's adjuvant on their tail base and rats were monitored for clinical signs of EAE from day 7 to day 40 p.i. (a) Plot of mean EAE score in DA rats compared with APLEC rats. (b) Cumulative and maximum EAE score, the duration and onset of EAE in DA and APLEC rats. **Po0.01; ***Po0.001; ****Po0.0001 using nonparametric Mann-Whitney test in GraphPad Prism 5.0. Error bars represent s.e.m. CUM, cumulative EAE score; MAX, maximum EAE score; DUR, duration of EAE; ONS, day of onset of EAE. C-type lectin-like genes control anti-MOG antibodies S Flytzani et al the Dcar1 gene carries a nonsense mutation that leads to a stop codon suggesting that Dcar1 might be nonfunctional. 19 Mincle also binds to the immunoreceptor tyrosine-based activating motifbearing adaptor molecule Fc receptor-g chain, suggesting activating function. 18 Mcl, Dcir3 and Dcir4 lack both features precluding predictions about signaling functions. However, additional functional studies of the APLEC encoding receptors are required in order to elucidate their role in EAE.
Anti-MOG antibodies have been shown to have an important role in rodent EAE. 32 Although the role of MOG as a prominent antibody target in MS is still under debate, 7 demyelinating antibodies of so far unknown specificity are present in the MS serum, 33 and thus our results may well be extrapolated to any other myelin antigen specificity. We here demonstrate that anti-MOG antibodies correlate with EAE susceptibility and severity. In addition to the quantitative differences between affected and healthy rats, with affected rats displaying higher IgG levels we investigated the potential qualitative differences in the humoral immune response, reflected by the pattern of IgG isotypes. In rat, IgG2b and IgG2c have been assigned to the Th1 response whereas the IgG1 subclass reflects a Th2-skewed immune response, 28, 34 which in the context of EAE might be protective. 35 In addition, in rodents, IgG1 isotype lacks complement-activating functions and displays much lower activatory/inhibitory ratio compared with IgG2b, 36 suggesting an inhibitory function of IgG1. The activatory/ inhibitory ratio is an indicator of the efficiency of the IgG isotypes in mediating effector responses 37 and is calculated by the ratio of activatory Fc receptor-g chain-binding affinity to inhibitorybinding affinity. 38 The protective role of IgG1 has also been shown in a mouse model of systemic lupus erythematosus, where progression of disease was correlated with increased production of anti-DNA IgG2a antibodies and decreased IgG1. 39 Furthermore, mice deficient in T-bet, Th1 cells transcription factor, were protected from lupus nephritis in association with lower levels of IgG2a and increased IgG1 levels. 40 In the present study, total anti-MOG IgG and IgG2b levels at the onset of EAE showed the best positive correlation with disease status and severity, while high levels of IgG1 correlated with milder EAE as well. However, we also show that the regulation of anti-MOG IgG isotype levels is polygenic and affected by both susceptible and resistant alleles. This emphasizes the importance of the relative contribution of different isotypes. Accordingly, the IgG1/IgG2b ratio remained higher throughout the disease course in the healthy rats and displayed negative correlation with disease severity, further suggesting the protective effect of IgG1 over IgG2b. This role is further supported by the APLEC congenic data. However, whether these isotypes have direct roles in EAE pathogenicity or reflect the type of mounted immune response remains to be studied.
Our study demonstrates a paradoxical situation, where an APLEC gene variant promotes higher levels of anti-MOG antibodies and in turn correlates to less severe disease. The antibody isotype, although, is Th2 driven, where the antibody effector functions may be benign, and the Th2-correlated anti-MOG T-cell immunity is the critical element for driving the relative protection. This basic finding is of potential importance in relation to a variety of immune-modulating, tolerogenic therapies promoting an antigenspecific Th2-biased immunity, in which fears have been raised that promotion of humoral anti-central nervous system immunity might be harmful. 41, 42 In conclusion, this study demonstrates complex genetic regulation of the anti-MOG IgG response during the initiation and progression of EAE. It also underscores that the quality of the C-type lectin-like genes control anti-MOG antibodies S Flytzani et al mounted antibody response contributes to disease outcome. Most notable is the effect of the APLEC genes, which skew the antibody response toward the Th2 pathway and thereby protect from EAE. Understanding how genetic regulation shapes anti-MOG IgG levels, and how these are involved in disease, can illuminate the mechanism of importance for EAE.
MATERIALS AND METHODS

Ethics statement
All experiments in this study were approved and performed in accordance with the guidelines from the Swedish National Board for Laboratory Animals and the European Community Council Directive (86/609/EEC) under the ethical permit N332/06 entitled 'Genetic regulation, pathogenesis and therapy of EAE, an animal model for multiple sclerosis', which was approved by the North Stockholm Animal Ethics Committee (Stockholms Norra djurfö rsö ksetiska nämnd). Rats were tested according to a health-monitoring program at the National Veterinary Institute (Statens Veterinärmedicinska Anstalt, SVA) in Uppsala, Sweden.
Animals and experimental crosses
Inbred DA and PVG.1AV1 rats were originally obtained from the Zentralinstitut fü r Versuchstierzucht (Hannover, Germany) from which colonies have been established at Karolinska Institutet (DA/Kini and PVG.1AV1/Kini). All animals were bred and kept in 12 h light/ dark-and temperature-regulated rooms. Rats were housed in polystyrene cages containing aspen wood shavings and had free access to standard rodent chow and water. Reciprocal backcrosses were established between DA-and major histocompatibility complex-identical PVG.1AV1 strains. To create the F1 generation, four breeding pairs with DA female founders were established. The reciprocal N2 generation was created from DA (n ¼ 4) and PVG.1AV1 (n ¼ 4) females bred to F1 males and F1 females bred to DA (n ¼ 4) or PVG.1AV1 (n ¼ 4) males. Four N2 litters were produced for serum collection and MOG-EAE experiments. The DABC consisted of 421 rats (213 females and 208 males) and the PVGBC consisted of 471 rats (239 females and 232 males). The AIL G10 cross has been previously described, and consisted of 794 rats (428 females and 366 males). 43 
APLEC congenic strain
Heterozygous congenic APLEC rats 19 were derived from an intercross between the DA and R11 strain 44 (15 backcross generations), followed by a backcross of one selected recombinant rat onto the DA background, resulting in 17 backcross generations. The strains contained PVG alleles on the DA background. Internal markers of the APLEC strain are: D4Kiru151, D4Kiru95, D4Kiru96, D4Kiru180, D4Kiru181, D4Kiru28, D4Kiru34, D4Kiru4 and D4Kiru55. External flanking markers are: D4Kiru152 and D4Kiru59.
Induction and clinical evaluation of EAE Recombinant rat MOG (amino acids 1-125 from the N terminus) was expressed in Escherichia Coli and purified to homogeneity by chelate chromatography. 45 Rats were anesthetized with isoflurane (Forene, Abbott Laboratories, Chicago, IL, USA) and immunized subcutaneously in the dorsal tail base. Each animal received a 200-ml inoculum containing MOG (females 12.5-40 mg and males 25-80mg) in phosphate buffered-saline (PBS; Life Technologies, Paisley, Scotland) emulsified 1:1 with incomplete Freund's adjuvant (Sigma-Aldrich, St Louis, MO, USA). EAE is a highly reproducible model with a robust clinical score scale. 46 Animals were weighed and clinical signs of EAE were evaluated daily from day 7 to 35 p.i. for the DABC, day 7-21 p.i. for the PVGBC and day 7-40 for the APLEC congenic strain. The scale for EAE scoring was: 0, healthy; 1, tail weakness or tail paralysis; 2, hind leg paresis or hemiparesis; 3, hind leg paralysis or hemiparalysis; 4, tetraplegy and 5, death. The following clinical parameters were assessed and used in analysis: incidence of EAE, that is, scored as 1 if signs of EAE were present for 41 day; onset of EAE, that is, the day of first clinical sign after immunization; duration of EAE (DUR), that is, number of days rats showed clinical signs; maximum EAE score (MAX); cumulative EAE score (CUM), that is, sum of all EAE scores recorded throughout the experiment; and weight loss, calculated by subtracting the lowest weight during the experiment from the weight at the time of immunization and expressing the difference as a percentage of the weight at the time of immunization. 
Anti-MOG isotype determination
Enzyme-linked immunosorbent assay was used to determine anti-MOG IgG, IgG1, IgG2b and IgG2c for each rat. Ninety-six-well enzyme-linked immunosorbent assay plates (Nunc, Roskilde, Denmark) were coated with 5 mg ml À 1 of rat recombinant MOG (amino acids 1-125) diluted in 0.1 M NaHCO3 (pH 8.2; 100 ml per well) overnight at 4 1C. Plates were washed twice with PBS/0.05% Tween-20 and free binding sites were blocked with 5% fat-free milk in PBS/0.05% Tween-20 for 1 h at room temperature. Rat sera were incubated in duplicates in plates for 1 h at room temperature.
The sera for measuring IgG antibody levels was diluted 1:10 000 (in both backcrosses and APLEC), for IgG1 isotype levels was diluted 1:200 (in DABC and APLEC) and 1:1000 (in PVGBC), for IgG2b isotype was diluted 1:2000 (in DABC and APLEC) and 1:10 000 (in PVGBC), and for IgG2c isotype was diluted 1:200 (in both backcrosses and APLEC). Plates were washed and incubated for 1 h at room temperature with rabbit anti-rat IgG (1:2000), IgG1 (1:1000), IgG2b (1:2000) or IgG2c (1:500; Nordic, Tilburg, The Netherlands). Unbound antibodies were removed by washing before the addition of a peroxidase-conjugated goat anti-rabbit antiserum (Nordic) diluted in PBS/0.05% Tween-20 (1:10 000). After 30 min incubation, plates were washed extensively and bound antibodies were visualized with 3,3 0 ,5,5 0 -tetramethylbenzidine (Sigma-Aldrich). The reaction was stopped by addition of 1 M HCl after 5-10 min in darkness and the optical density was read at 450 nm using an Emax Microplate Reader (Molecular Devices, Sunnyvale, CA, USA). Seven twofold dilutions of serum samples from rats with high levels of each isotype detected in a pilot study were included on each plate to create a standard curve and to permit interplate comparisons. The protocol used to determine anti-MOG isotypes in the AIL G10 has previously been described. 43 
Genotyping
Genomic DNA was extracted from tail tips. Genotypes were determined by PCR amplification of microsatellite markers. Fluorophore-conjugated primers were used (Applied Biosystems, Eurofins MWG Operon, Foster City, CA, USA) and PCR products were size-fractionated on an electrophoresis capillary sequencer (ABI3730, Applied Biosystems). Genotypes were analyzed using the GeneMapper software (v. 3.7, Applied Biosystems) and all genotypes were manually confirmed by two independent observers.
Statistical and linkage analysis
The genetic map was defined using publicly available genome sequence (http://www.ensembl.org/RGSC3.4). The physical map was used to enable comparison of linkage analyses between crosses and sub-populations. All animals were genotyped with 137 evenly spaced microsatellite markers providing 97% and 91% genome coverage with 25cM and 20cM spacing, respectively. Antibody values were transformed by the square root to achieve a normal distribution. Linkage analysis was performed using R/qtl software version 2.11.1. 47 A single-QTL model analysis was performed using Haley-Knott regression. 48 For the backcrosses, permutation tests (N ¼ 1000) were performed to determine the threshold levels for significant linkage, and genome-wide Po0.05 thresholds were reported. 49 For the AIL, family residual values previously described were used to determine significant thresholds. 43 Allelic effects of QTLs identified in the backcrosses, differences in antibody levels between healthy and sick rats and comparison of APLEC and DA strains were calculated in GraphPad Prism 5.0 (Graph Pad, San Diego, CA, USA) using nonparametric Mann-Whitney test for all phenotypes except for incidence that was tested with the Fisher's exact test. Allelic effect of QTLs in the AIL G10 were calculated using KruskalWallis with Dunn's multiple comparison test in GraphPad Prism 5.0. Spearman's rank correlations between antibody levels and clinical EAE phenotypes were calculated in Rcmdr.
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